Since 2011, WeHaveAFace has been a firm supporter and friend of the Huntington Study Group (HSG). Among the many facets of our mission as an international organization is to broaden education and awareness of all Huntington's studies and trails. It is imperative that our global community receive the necessary information regarding current studies and trails. Through our multimedia approach for advocacy, we are pleased to report that tens of thousands of our patients and families have accessed information on trials and studies, via our international mobile application. With over 125,000 active daily users, this resource also plays a significant role in patient and caregiver feedback. WeHaveAFace has been successful in assisting our patients and caregivers with quick and accurate information about all studies and trials via the HSG. By harnessing technology and social networking, a "mobile approach" for trials and studies, has been successful.
On Monday, August 27, 2018, WeHaveAFace will be hosting a "WeHaveAVoice" radio show with Elise Kayson (HSG, Director of Clinical and Strategic Initiatives), and Dr. Andrew Feigin (Professor of Neurology at NYU Langone Health).
As per the HSG website: "The Huntington Study Group (HSG) is pleased to announce that Andrew Feigin, MD, and Elise Kayson, MS, ANP, have been elected as the chair and co-chair, respectively, of HSG, a world-wide network of Huntington disease (HD) researchers. Both Feigin and Kayson have dedicated their careers to the clinical care of patients and families and research in HD."
So, what is the SIGNAL trail?
The HSG notes that, "Vaccinex and the Huntington Study Group (HSG) launched a trial for people with the gene mutation that causes HD who are either early in the progression of the disease or are not yet diagnosed with the disease.
The SIGNAL trial is designed to assess the safety, tolerability, and effectiveness of VX15, a novel monoclonal antibody, in people with late prodromal (not yet diagnosed) or early manifest (early in the progression of the disease) HD. It is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study being conducted at approximately 30 sites across the United States and Canada. The trial seeks to enroll a total of 240 individuals, 21 or older.
The trial has two cohorts. Cohort A, which consisted of the trial’s first 36 participants, is now complete. Those participants were treated for six months with either drug or placebo (1:1); then all participants were treated with study drug for six months, followed by three months of follow up.
It may be quite difficult to understand what takes place within studies and trials. WeHaveAFace recognizes that many within our community are concerned with the verbiage...the procedures...and so much more. WeHaveAFace will do our best to help you understand exactly what the SIGNAL trails is! Stay tuned for this special upcoming WeHaveAVoice radio show!
If you have any questions regarding the SIGNAL trail, please visit the WeHaveAVoice radio page and we will read your question during the show!
*Complete details on the SIGNAL trail via the HSG website.